Abstract: The invention relates to novel mTOR inhibitor compounds having the formula (I) or a pharmaceutically acceptable salt thereof, compositions comprising the mTOR inhibitor compounds, methods for producing the same, and the use thereof.
Abstract: The invention relates to novel mTOR inhibitor compounds having the general formula (I), to compositions comprising said mTOR inhibitor compounds, methods for producing same, and the use thereof in compositions as a drug.
Abstract: A method for evaluating skin conditions on a skin area of a user using an ultraviolet light device that can connect to a mobile device and a user input is disclosed. The method for evaluating skin conditions includes the steps of illuminating the skin area of the user with the ultraviolet light device operated by the mobile device, capturing an image of the illuminated skin area with an image capture device, processing the image with a processing program to determine the level of fluorescence on the skin area, and mapping progress of treatment of the skin condition based on the processed image compared to a control image.
Abstract: A method of preventing or reducing dermatological side effects of the therapeutic agents in a subject without substantial loss in efficacy, where the therapeutic agents would otherwise have significant effects, is described. In particular, the beneficial effects are achieved by using an alpha-2 adrenergic agonist to isolate body areas from pharmacological effects of the therapeutic agents, such as a chemotherapeutic agent, and to prevent or reduce inflammatory processes.
Abstract: A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a diol portion of a diol-functional moiety grafted to a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.
Type:
Application
Filed:
November 24, 2021
Publication date:
March 17, 2022
Applicants:
Galderma Research & Development, Centre National de la Recherche Scientifique
Inventors:
Rachel AUZELY-VELTY, Tamiris FIGUEIREDO, Laura JING JING, Craig Steven HARRIS, Jean-Guy BOITEAU, Thibaut GERFAUD, Loic TOMAS
Abstract: A self-foaming composition is described that includes brimonidine, for a no-rinse topical application. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and brimonidine or one of the pharmaceutically acceptable salts thereof being present in at least one of the intermediate compositions A and B. Also described, is a kit or a single container including a plurality of compartments including such a composition.
Abstract: A composition is described that includes at least one lactic acid bacteria, preferably Lactobacillus johnsonii LA1 NCC 533 (deposit number CNCM I-1225) in an acceptable carrier. Also described, is use of the composition in the treatment and/or prevention of a dermatological disease, preferably atopic dermatitis.
Abstract: A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a diol portion of a diol-functional moiety grafted to a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.
Type:
Grant
Filed:
August 2, 2017
Date of Patent:
January 4, 2022
Assignees:
GALDERMA RESEARCH & DEVELOPMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTFIQUE
Inventors:
Rachel Auzely-Velty, Tamiris Figueiredo, Laura Jing Jing, Craig Steven Harris, Jean-Guy Boiteau, Thibaut Gerfaud, Loic Tomas
Abstract: A method is described for using IL-12R?1/IL-23R, CCR6, BATF, AHR, STAT3, IRF4 crucial actors in TH17 cells differentiation as markers for acne. Also described are methods of their use to diagnose acne, and to screen inhibitors of Th17 differentiation. In particular, methods are described for inhibiting IL12R?1/1L-23R, CCR6, BATF, AHR, STAT3, IRF4 and the use of these screened inhibitors in acne treatment.
Abstract: A composition is described that includes lipid microcapsules and at least one dispersed active principle. A method is also described for preparing the composition. Also described, is the use of the composition in the treatment of dermatological diseases.
Type:
Grant
Filed:
May 27, 2016
Date of Patent:
December 14, 2021
Assignee:
GALDERMA RESEARCH AND DEVELOPMENT
Inventors:
Carole Dubayle, Claire Mallard, Nicolas Atrux-Tallau
Abstract: A self-foaming composition is described that includes clobetasol propionate, for a no-rinse topical application and for application to the skin. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and clobetasol propionate being present in at least one of the intermediate compositions A and B. Also described, is a kit or a single container including a plurality of compartments including such a composition.
Abstract: A self-foaming composition is described that includes trifarotene, for a no-rinse topical application. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and trifarotene or one of the pharmaceutically acceptable salts thereof being present in at least one of the intermediate compositions A and B. The composition is particularly intended for the treatment of ichthyosis. Also described, is a kit or a single container including a plurality of compartments including such a composition.
Abstract: A self-foaming composition is described that includes trifarotene, for a no-rinse topical application and for application to the skin. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and trifarotene or one of the pharmaceutically acceptable salts thereof being present in at least one of the intermediate compositions A and B. The composition is particularly intended for the treatment of acne. Also described is a kit or a single container including a plurality of compartments including such a composition.
Abstract: Compounds of general formula (I) are described. Also described, is the use of such compounds in pharmaceutical compositions for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmologic disorders, in particular), or in cosmetic compositions.
Abstract: A self-foaming composition is described that includes ivermectin, for a no-rinse topical application and for application to the skin. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and ivermectin being present in the composition A, in the composition B, or simultaneously in the two compositions A and B. Also described, is a kit or a single container including a plurality of compartments including such a composition.
Abstract: The invention relates to a method for determining in vitro release rate of at least one active principle ingredient from at least one semisolid form.
Abstract: A method is described for producing an oil-in-water emulsion including oil globules, the mean diameter of which is less than 500 nm and each of which is provided with a lamellar liquid crystal coating, and which are dispersed in an aqueous phase. Each oil globule is individually coated with a unilamellar or oligolamellar layer obtained from at least one lipophilic surfactant, at least one hydrophilic surfactant, and at least one separate anionic surfactant, characterized in that the number of steps in the method is no greater than 5, in that the temperatures used during the different steps are no higher than 75° C., and in that the method requires neither the use of a high-pressure homogenizer nor any pre-emulsification step.